Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04556435
Recruitment Status : Not yet recruiting
First Posted : September 21, 2020
Last Update Posted : September 21, 2020
Sponsor:
Collaborator:
University of California, Irvine
Information provided by (Responsible Party):
Picomole Inc

Brief Summary:
The aim of this study is to sample and analyze volatile organic compounds (VOCs) from lung cancer patients and individuals without lung cancer ("healthy" controls). The breath sample analysis will help investigators describe and identify profiles of VOCs found in the breath of patients with lung cancer when compared to normal breath profiles using infrared spectroscopy. This work will help validate early proof of concept results conducted with prototype technology and later stage NSCLC breath samples, and inform future breath testing analysis.

Condition or disease
Lung Cancer Non Small Cell Lung Cancer

Detailed Description:
Globally, lung cancer accounts for the most cancer deaths in both sexes combined. It is believed to develop slowly through progressive accumulation of genetic mutations, hence the disease allows time for diagnosis and curative surgical treatment. Five year survival rates for non-small-cell lung carcinoma (NSCLC) can range from 57-61% when detected in the early stages of disease. This is compared with a survival rate of approximately 6% once distant metastases are present. However, disease diagnosis typically occurs when it has progressed to an advanced stage when patients present with signs and symptoms. Therefore, technologies capable of asymptomatic disease detection will significantly impact lung cancer specific mortality. Metabolomic profiling of cancer measures compounds produced as a result of cellular activity including volatile organic compounds (VOCs) in exhaled breath. Infrared spectroscopy is a proven technique for breath analysis that can measure chemical concentrations in the parts per trillion range for certain VOCs. When coupled with machine learning techniques, this has the potential to be a novel approach for disease detection using exhaled breath.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Analysis of Volatile Chemicals in the Breath of Lung Cancer Patients Using Infrared Spectroscopy
Estimated Study Start Date : October 1, 2020
Estimated Primary Completion Date : February 22, 2021
Estimated Study Completion Date : March 15, 2021

Resource links provided by the National Library of Medicine


Group/Cohort
LC Group
Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health). Information related to LC diagnosis (histologic sub-type, tumor stage) will be collected.
Control Group
Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health).



Primary Outcome Measures :
  1. VOC spectral profile differences [ Time Frame: 30 days after completion ]
    VOC spectral profiles will be compared between cohorts to identify statistical differences.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
This study will analyze breath samples from study participants with diagnosed lung adenocarcinoma not currently receiving curative treatment and matched control participants without lung cancer. Prospective participants will be pre-screened prior to being approached about the study. Those scheduled for upcoming appointments will undergo a chart review to determine whether they meet eligibility criteria.
Criteria

Inclusion Criteria

LC Group:

  • ≥ 18 years;
  • Able to give informed consent;
  • Eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery);
  • Clinical evidence of lung cancer (metastatic or primary), inclusive of those receiving non-curative treatment, has not yet been treated or is not currently on treatment;
  • No history of or any other active cancer;
  • Able to provide a breath sample;

Control Group:

  • ≥ 18 years;
  • Able to give informed consent;
  • Eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery);
  • No history of lung cancer or any other active cancer and is eligible for lung cancer screening;
  • Able to provide a breath sample;

Exclusion Criteria

  • Has received or is currently receiving curative treatment and may no longer have lung cancer;
  • Cannot give informed consent;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04556435


Contacts
Layout table for location contacts
Contact: Carlos Chavez, MD 714-456-5396 chavezc@hs.uci.edu
Contact: Cesar Figueroa, MD figuerc1@hs.uci.edu

Locations
Layout table for location information
United States, California
University of California, Irvine Medical Center
Orange, California, United States, 92868
Contact: Carlos Chavez, MD    714-456-5396    chavezc@hs.uci.edu   
Contact: Cesar Figueroa, MD       figuerc1@hs.uci.edu   
Sponsors and Collaborators
Picomole Inc
University of California, Irvine
Investigators
Layout table for investigator information
Principal Investigator: Ali Mahtabifard, MD University of California, Irvine
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Picomole Inc
ClinicalTrials.gov Identifier: NCT04556435    
Other Study ID Numbers: 2019-5606
First Posted: September 21, 2020    Key Record Dates
Last Update Posted: September 21, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan to make IPD available.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Picomole Inc:
Volatile Organic Compounds
Breath Analysis
Infrared Spectroscopy
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases